Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatitis C virus (HCV) genotype 1a or 1b infection confirmed before randomization~* Documentation of the presence or absence of a NS3 Q80K polymorphism in HCV genotype 1a infected participants before randomization~* Documentation of the IL28B genotype before randomization~* HCV ribonucleic acid level greater than 10,000 IU/mL at screening~* Treatment-experienced participants must have at least 1 documented previous course of interferon-based regimen with or without ribavirin~* Absence of cirrhosis in participants~Exclusion Criteria:~* Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)~* Infection/co-infection with HCV non-genotype 1a or 1b~* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)~* Co-infection with hepatitis-B virus (hepatitis-B-surface-antigen positive)~* Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Simeprevir/Sofosbuvir) (Type: EXPERIMENTAL): 150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
- Arm 2 (Simeprevir/Sofosbuvir) (Type: EXPERIMENTAL): 150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).